Pictured: Moritz Kircher
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, April 25, 2012

Researchers have demonstrated a technique that enables specific and accurate labeling of brain tumor tissue in mice. If proven effective in patients, the method could make complete surgical removal of brain tumors more feasible.

Pictured: Patty
Patient Story
By Memorial Sloan Kettering  |  Monday, April 23, 2012

Patty grew up playing in the sun at the beach, so when she developed a growth under her eye she knew it could be skin cancer. Experts at Memorial Sloan Kettering Basking Ridge diagnosed her with basal cell carcinoma and performed a highly specialized surgery to remove the cancer.

Pictured: Jedd Wolchok and James Allison
In the News
By Media Staff  |  Friday, April 20, 2012

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.

Pictured: James Eastham
Video
By Memorial Sloan Kettering  |  Monday, April 16, 2012

James Eastham, Chief of Memorial Sloan Kettering’s Urology Service, talks about how our prostate cancer experts collaborate to maximize the likelihood of curing the cancer and limiting the side effects of treatment.

Pictured: Bruce
Patient Story
By Memorial Sloan Kettering  |  Monday, April 9, 2012

A routine blood test led to a diagnosis of bone cancer for Bruce, an otherwise healthy 43-year-old writer. Surgeons at Memorial Sloan Kettering removed his cancer and saved his leg, giving him the chance to resume his career as “the writer who walks.”

Pictured: T cells on surface on thymus
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, April 6, 2012

A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.

Pictured: American Association of Cancer Research Annual Meeting 2012
Announcement
By Media Staff  |  Tuesday, April 3, 2012

The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.

Pictured: Sergio Giralt
Q&A
By Memorial Sloan Kettering  |  Monday, March 26, 2012

Adult Bone Marrow Transplantation Service Chief Sergio Giralt explains recent advances that are enabling more patients to survive the most difficult period after receiving a transplant.

Pictured: Elizabeth Morris
In the O.R.
By Esther Napolitano, BS and Allyson Collins, MS
Friday, March 16, 2012

Memorial Sloan Kettering is the first and only hospital in New York, New Jersey, and Connecticut to offer a new, more patient-friendly approach for doctors to precisely pinpoint and remove small breast cancers.

Pictured: Ross Levine
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Thursday, March 15, 2012

Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).

Pictured: Peter Scardino
Q&A
By Memorial Sloan Kettering  |  Monday, March 12, 2012

Department of Surgery Chair Peter T. Scardino reflects on the expanding role of surgery at an institution devoted to caring for people with cancer.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, March 8, 2012

Findings from a multidisciplinary research team led by Memorial Sloan Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Pictured: Mark Bilsky
Q&A
By Memorial Sloan Kettering  |  Wednesday, February 15, 2012

The director of the Spine Tumor Center explains how this new, high-powered approach to radiation therapy has changed the way spine tumors are treated at Memorial Sloan Kettering.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Tuesday, February 7, 2012

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

Pictured: Memorial Sloan Kettering logo
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, February 6, 2012

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

Center News

Stay Informed

Get the latest information about cancer care and research every month.